---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035311"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:10:50.862642+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma announces departure of President of R&D and CMO Gregory Berk

## Summary
- Dr. Gregory Berk no longer employed as President of R&D and Chief Medical Officer effective December 8, 2022.
- No successor or interim replacement named in the filing.
- Departure comes as GT Biopharma (GTBP) advances its cancer immunotherapy pipeline.

## SEC filing metadata
- accession: 0001493152-22-035311
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315222035311/0001493152-22-035311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315222035311/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035311
- JSON: https://secwatch.observer/filing/0001493152-22-035311.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035311.txt

## Key facts
- Executive change
  Gregory Berk departed as President of Research & Development and Chief Medical Officer at GT Biopharma, Inc..
  - Action: no longer employed
  - Role: President of Research & Development and Chief Medical Officer
  source text: Effective December 8, 2022, Dr. Gregory Berk, President of Research & Development and Chief Medical Officer, is no longer employed by the Registrant.
  evidence_url: https://www.sec.gov/Archives/edgar/data/109657/000149315222035311/0001493152-22-035311-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.